The omega-3 index: testing, dosing and what the evidence shows
The omega-3 index is the percentage of EPA plus DHA in your red blood cell membranes, a stable marker of long-term omega-3 status rather than what you ate yesterday. A value of 8 percent or above is the proposed target; most people in the UK, US and northern Europe sit nearer 4 to 5 percent. Raising it reliably takes roughly 1 to 2 grams of combined EPA and DHA daily for three to four months. Whether that translates into fewer heart attacks is genuinely contested, and this guide grades the evidence honestly.
Key facts
- The omega-3 index measures EPA plus DHA as a percentage of total fatty acids in red blood cell membranes. It was proposed as a coronary risk marker by Harris and von Schacky in 2004.1
- The suggested target is 8 to 11 percent; risk rises below 8 percent and is highest under 4 percent. Typical Western levels are around 4 to 5 percent.12
- About 1 gram per day of EPA plus DHA for roughly 20 weeks moved healthy adults from a 4 to 5 percent baseline to above 8 percent in a dose-response trial.3
- The cardiovascular trial evidence is split: REDUCE-IT was positive, while VITAL and STRENGTH were neutral. The placebo used in REDUCE-IT is a major reason for the disagreement.567
What the omega-3 index actually measures
Eat oily fish or take fish oil and the long-chain omega-3 fats EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are slowly built into the membranes of your cells, including red blood cells. Because red cells live about four months, their fatty-acid make-up reflects your average intake over the preceding months, not a single meal. The omega-3 index expresses EPA plus DHA as a percentage of all the fatty acids in that membrane. Harris and von Schacky proposed it in 2004 as a coronary heart disease risk marker, arguing it was more stable and more biologically meaningful than a one-off plasma reading.1
This is why it belongs in the same family of structural, slow-moving biomarkers as ferritin or HbA1c: it tells you about a pool, not a moment. A fasting plasma omega-3 reading bounces around with your last meal; the red cell index does not.
Target ranges and typical Western deficiency
The proposed optimal band is 8 to 11 percent. In the original analyses, an index above 8 percent was associated with the lowest risk of death from coronary heart disease, an index of 4 to 8 percent was intermediate, and below 4 percent carried the highest risk.1 Levels above 11 percent do not appear to add further benefit.
The uncomfortable backdrop is that most Western populations fall well short. A global review by Stark and colleagues, synthesising data from 1980 to 2014, found that EPA and DHA typically make up only about 3 to 5 percent of red cell fatty acids across the Americas, much of Europe and the Middle East, with higher levels concentrated in populations eating a lot of seafood, such as Japan and parts of Scandinavia.2 In other words, a typical UK adult who rarely eats oily fish is likely sitting in the intermediate-to-low range by default.
| Omega-3 index | Category | What it suggests |
|---|---|---|
| Above 8 percent | Desirable | Target zone; associated with the lowest coronary risk in observational data. |
| 4 to 8 percent | Intermediate | Where most Western adults with modest fish intake sit. |
| Below 4 percent | Low | Highest-risk band in the original framework; common in very low fish intakes. |
EPA versus DHA, and the dose needed to move the number
EPA and DHA are not interchangeable when it comes to the index. DHA is incorporated into red cell membranes more directly and efficiently, so gram for gram it tends to raise the omega-3 index more than EPA does; EPA can elongate to DHA in the body, but DHA does not meaningfully convert back.4 For raising the index specifically, DHA does more of the lifting, though EPA carries much of the triglyceride-lowering and signalling activity.
How much is needed? In a dose-response randomised trial, Flock and colleagues found that supplemental EPA plus DHA explained roughly 68 percent of the variation in the index response, and that around 1 gram per day for about 20 weeks took healthy adults from a baseline near 4 to 5 percent up past 8 percent.3 Response varies with body weight, baseline level and genetics, so heavier people or those starting very low often need 2 grams per day or more. The practical rule of thumb: pick a dose, hold it for three to four months, then retest, because the membrane pool turns over slowly. A structured supplement plan makes that kind of consistency easier to sustain.
Evidence strength: the dose-response relationship between EPA plus DHA intake and the red cell index is well established across controlled trials.3 What remains less certain for any individual is the exact dose, because absorption and baseline status vary widely. Testing, rather than assuming, is the honest approach.
The mixed cardiovascular evidence: REDUCE-IT, VITAL and STRENGTH
This is where caution is essential. Three large trials reached different conclusions, and reconciling them is the crux of the omega-3 debate.
VITAL (Manson and colleagues, NEJM 2018) randomised 25,871 generally healthy US adults to 1 gram of fish oil daily or placebo. Over a median 5.3 years it found no significant reduction in its primary endpoint of major cardiovascular events or in total cancer, though subgroup analyses hinted at benefit in people with low baseline fish intake.5 This is the best evidence that a modest 1 gram dose does not move hard outcomes in a well-nourished general population.
REDUCE-IT (Bhatt and colleagues, NEJM 2019) was different: 8,179 statin-treated patients with raised triglycerides and high cardiovascular risk received a high dose, 4 grams daily, of purified EPA (icosapent ethyl). It reported a striking 25 percent relative reduction in its primary composite endpoint.6 Taken alone, that looks decisive.
STRENGTH (Nicholls and colleagues, JAMA 2020) then tested a comparable 4 gram dose of a combined EPA and DHA formulation in 13,078 high-risk patients and found no benefit at all (hazard ratio 0.99).7 Both high-dose trials, opposite results.
The likeliest explanation for the gap is the placebo. REDUCE-IT used a mineral oil placebo, and the placebo group showed rises in LDL cholesterol (around 10 percent) and inflammatory markers, which may have exaggerated the apparent benefit. STRENGTH used a corn oil placebo, which did not move those markers.8 Both high-dose trials also reported more atrial fibrillation in the omega-3 arm, a genuine safety signal worth knowing.67
The honest summary: a higher omega-3 index is consistently associated with lower cardiovascular risk in observational data, but proving that supplements cause better outcomes has been inconsistent and dose-dependent, and the one strongly positive trial is shadowed by its placebo choice. Purified high-dose EPA in high-triglyceride, statin-treated patients has the best case; routine low-dose fish oil for healthy people does not show a clear outcome benefit. We cover this kind of association-versus-causation gap further in our insights.
Fish, algae or supplements, and UK guidance
You can raise the index three ways. Oily fish (salmon, mackerel, sardines, herring) is the most food-first route and brings protein and micronutrients with it. Fish oil supplements deliver a measured dose, useful if you do not eat fish. Algae oil is the original source of EPA and DHA, the fish merely concentrate it from algae, and is a genuine plant-based option; most algal products are DHA-rich, which suits index-raising, and some now add EPA. Check the EPA plus DHA content on the label, not the total oil weight, which is often much higher.
UK guidance is pragmatic. The NHS advises at least two portions of fish a week, one of them oily (a portion is about 140 grams), and the Scientific Advisory Committee on Nutrition recommends roughly 450 mg of combined EPA and DHA per day for adults.9 Note this population advice aims at general health, not at hitting an 8 percent index, which usually requires more than two weekly portions or a supplement. Women who are pregnant, breastfeeding or may become pregnant are advised to limit oily fish to no more than two portions a week because of pollutants.9 If you are weighing this alongside other decisions, our start page is a good orientation point.
- Given my heart risk and triglycerides, is there a case for prescription icosapent ethyl rather than over-the-counter fish oil?
- I have palpitations or a history of atrial fibrillation: is high-dose omega-3 sensible for me?
- Should my triglycerides and overall lipid picture be reviewed before I start a high dose?
- Is omega-3 index testing available locally, or is it something I would arrange privately?
References
- Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212-220. PMID 15208005.
- Stark KD, Van Elswyk ME, Higgins MR, et al. Global survey of the omega-3 fatty acids, EPA and DHA in the blood stream of healthy adults. Prog Lipid Res. 2016;63:132-152. PMID 27216485.
- Flock MR, Skulas-Ray AC, Harris WS, et al. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. J Am Heart Assoc. 2013;2(6):e000513. JAHA.
- Walker RE, Jackson KH, Tintle NL, et al. Predicting the effects of supplemental EPA and DHA on the omega-3 index. Am J Clin Nutr. 2019;110(4):1034-1040. PMID 31396625.
- Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL). N Engl J Med. 2019;380(1):23-32. NEJMoa1811403.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. NEJMoa1812792.
- Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH). JAMA. 2020;324(22):2268-2280. PMID 33190147.
- Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. Eur Heart J. 2021;42(47):4807-4817. PMID 34455435.
- NHS. Fish and shellfish: eat well. National Health Service. nhs.uk.
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.